Citations

Clear

861 citation(s) found for "Sd, Wexner".

Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Wei, Lai , Chen, Wei , Mikhail, Sameh , Ciombor, Kristen K. , Cardin, Dana B. , Timmers, Cynthia , Krishna, Somashekar G. , Abdel‐Misih, Sherif , Roychowdhury, Sameek , Bekaii‐Saab, Tanios , Wuthrick, Evan , Wei, Lai , Chen, Wei , Cardin, Dana B , Krishna, Somashekar G , Arnold, Mark , Abdel-Misih, Sherif , Bekaii-Saab, Tanios S , Wu, Christina , Williams, Terence M. , Robb, Ryan N. , Webb, Amy , Harzman, Alan

Mayo Clinic

Clinical Cancer Research | April 6, 2020 | Volume: 26 | Issue: 13 | Pages: 3117-3125

10.1158/1078-0432.ccr-19-4193 | PMID 32253228 Get It

Abstract Purpose: The RAS/RAF/MEK/ERK signaling pathway is critical to the development of colorectal cancers, and KRAS, NRAS, and BRAF mutations foster resistance to radiation. We performed a phase I trial to determine the safety of trametinib, a potent MEK1/2 inhibitor, with 5-fluorouracil (5-FU) chemoradiation therapy (CRT) in patients with locally advanced rectal cancer (LARC). Patients and Methods: Patients with stage II/III rectal cancer were enrolled on a phase I study with 3+3 study design, with an expansion cohort of 9 patients at the MTD. Following a 5-day trametinib lead-in, with pre- and posttreatment tumor biopsies, patients received trametinib and CRT, surgery, and adjuvant chemotherapy. Trametinib was given orally daily at 3 dose levels: 0.5 mg, 1 mg, and 2 mg. CRT consisted of infusional 5-FU 225 mg/m2/day and radiation dose of 28 daily fractions of 1.8 Gy (total 50.4 Gy). The primary endpoint was to identify the MTD and recommended phase II dose. IHC staining for phosphorylated ERK (pERK) and genomic profiling was performed on the tumor samples. Results: Patients were enrolled to all dose levels, and 18 patients were evaluable for toxicities and responses. Treatment was well tolerated, and there was one dose-limiting toxicity of diarrhea, which was attributed to CRT rather than trametinib. At the 2 mg dose level, 25% had pathologic complete response. IHC staining confirmed dose-dependent decrease in pERK with increasing trametinib doses. Conclusions: The combination of trametinib with 5-FU CRT is safe and well tolerated, and may warrant additional study in a phase II trial, perhaps in a RAS/RAF-mutant selected population.
Towards Estimation of Three-Dimensional Knee Rotations
McPherson, April L. , Felton, Christopher L. , Hale, Rena F. , Gilbert, Barry K., Schilaty, Nathan D. , Hewett, Timothy E. , Holmes, David R. , Haider, Clifton R. , Schilaty, Nathan D , Felton, Christopher L

Mayo Clinic

2019 53rd Asilomar Conference on Signals, Systems, and Computers | March 31, 2020 | Volume: No volume available | Issue: No issue available | Pages: 1359-1363

10.1109/ieeeconf44664.2019.9048749 Get It

Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network
King, Tari A. , Liu, Minetta C. , Hinoue, Toshinori , Kelly, Benjamin , Creighton, Chad J. , Leraas, Kristen , Burns, Robyn, Coppens, Sara E. , Rezk, Salma, Garrett, Amy, Balko, Justin M. , Krop, Ian E. , Rimawi, Mothaffar F. , Nanda, Rita , Storniolo, Anna Maria , Chandran, Uma , Richardson, Andrea L. , Davidson, Nancy E. , Network, the AURORA US, Wrangle, John M , Rimawi, Mothaffar , McClure, Marni B. , Bowen, Jay , Parker, Joel S. , Park, Ben Ho , Anders, Carey K. , Hoadley, Katherine A. , Gastier‐Foster, Julie M. , Lin, Nancy U. , Isaacs, Claudine , Marcom, Paul Kelly , Couch, Fergus J. , Mardis, Elaine R. , Lee, Adrian V. , Laird, Peter W. , Hilsenbeck, Susan Galloway , Norton, Larry , Symmans, W. Fraser , Carey, Lisa A. , Wolff, Antonio C. , Perou, Charles M. , Network, the AURORA US

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: GS3-08-GS3-08

10.1158/1538-7445.sabcs19-gs3-08 Get It

Abstract Background: It has become increasingly clear that effective treatment of metastatic breast cancer (MBC) requires an in-depth understanding of the molecular differences between primary tumors and metastases. The AURORA US Network was established to collect primary breast cancer-metastasis pairs for multi-platform genomic profiling in order to identify the molecular drivers of metastatic disease. AURORA US has both a retrospective and prospective phase. This is the first report of the retrospective phase. Methods: Archived tissue samples from the primary tumor and at least one distant metastasis were retrospectively collected from 83 MBC patients. Following internal quality assessment, samples from 55 pts, including 105 distinct metastatic lesions, were subject to DNA low pass whole genome and exome sequencing, DNA methylation arrays, and RNA sequencing. Early analyses of these multi-platform data include: DNA methylation, tumor gene expression and microenvironmental signatures, somatic and germline variants, DNA copy number changes, and structural variants between breast primaries and matched metastases. Results: Median age at diagnosis was 49 years (25-76); 32 (58%) were Stage I or II at presentation, 27 (49%) had a family history of breast cancer, and 20 (36%) had a second breast primary. Median disease-free interval before developing MBC was 2 years (range 0-36, 5 patients presented with Stage IV). Median overall survival from initial presentation was 4 years (range 0-37). Median survival after developing MBC was 1 year (range 0-13), with a median of three treatments. Primary tissue samples were banked from 1977-2017 and metastases were banked from 1999-2017. Clinical phenotypes of the primaries included 27 HR+ (49%), 15 triple negative (TNBC, 27%), and 11 HER2+ (20%, 12 missing HER2 status). Intrinsic subtype distribution of the primaries included 17 Basal-like (31%), 17 Luminal A (31%), 7 Normal-like (13%), 5 HER2-enriched (9%), and 1 Luminal B, with 8 pending. All metastases from the Basal-like cases remained Basal-like, while metastases from luminal primaries tended to gain HER2-Enriched subtype features (5/18, p = 0.01). Overall, we identified significant metastasis-enriched alterations in metabolism pathways, an increase in proliferation, and the loss of differentiation signatures and immune infiltrates with progression; the latter being the most pronounced in brain metastases. The most frequent somatic mutations in this cohort were in TP53, NCOR1, and RUNX1. Interestingly, ERBB2, EGFR, and ATM were also mutated in ≥10% of the tumors sequenced. In almost all cases, CpG island hypermethylation was clonally present in the primary tumor and persisted stably in the majority of metastatic lesions. Promoter CpG island hypermethylation was also identified in some metastatic lesions at JAM3, an important cellular adhesion molecule,and this was accompanied by reduced mRNA expression. CONCLUSIONS: Collection of banked primary and metastatic tissue pairs identified a young MBC cohort with a high frequency of breast cancer family history and second breast primaries. Molecular characterization of luminal tumor pairs highlighted acquisition of aggressive traits including increased proliferation and loss of differentiation in the metastases. In contrast, basal-like pairs remained relatively unchanged, except for the loss of immune activation. Ongoing analyses to be presented include clonal heterogeneity and phylogeny, novel metastasis signature discovery, gene fusion, and endogenous retrovirus detection. Citation Format: Tari A King, Minetta C Liu, Marni B McClure, Toshinori Hinoue, Benjamin J Kelly, Chad J Creighton, Jay Bowen, Kristen Leraas, Robyn T Burns, Sara Coppens, Salma Rezk, Amy L Garrett, Justin M Balko, Joel S Parker, Ben H Park, Ian Krop, Carey Anders, Katherine A Hoadley, Julie Gastier-Foster, Mothaffar F Rimawi, Rita Nanda, Nancy U Lin, Claudine Isaacs, P. Kelly Marcom, Anna Maria Storniolo, Fergus J Couch, Elaine R Mardis, Adrian V Lee, Uma Chandran, Peter W Laird, Susan G Hilsenbeck, Larry Norton, Andrea L Richardson, W. Fraser Symmans, Lisa A Carey, Antonio C Wolff, Nancy E Davidson, Charles M Perou, the AURORA US Network. Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr GS3-08.
Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology,
Apovian, Caroline M., Brethauer, Stacy A., Joffe, Aaron M. , Kushner, Robert F. , Lindquist, R R , Pessah‐Pollack, Rachel , Seger, Jennifer, Adams, Stephanie, Cleek, John B., Correa, Riccardo , Figaro, M. Kathleen, Flanders, Karen, Grams, Jayleen , Hurley, Daniel L. , Kothari, Shanu N. , Seger, Michael, Still, Christopher D. , Mechanick, Jeffrey I. , Garvey, William Timothy , Kim, Julie , Lindquist, Richard, Urman, Richard D , Seger, Michael V.

Mayo Clinic

Obesity | March 23, 2020 | Volume: 28 | Issue: 4 | Pages: No page available

10.1002/oby.22719 | PMID 32202076 Get It

Objective The development of these updated clinical practice guidelines (CPGs) was commissioned by the American Association of Clinical Endocrinologists (AACE), The Obesity Society (TOS), American Society for Metabolic and Bariatric Surgery (ASMBS), Obesity Medicine Association (OMA), and American Society of Anesthesiologists (ASA) Boards of Directors in adherence with the AACE 2017 protocol for standardized production of CPGs, algorithms, and checklists. Methods Each recommendation was evaluated and updated based on new evidence from 2013 to the present and subjective factors provided by experts. Results New or updated topics in this CPG include: contextualization in an adiposity‐based chronic disease complications‐centric model, nuance‐based and algorithm/checklist‐assisted clinical decision‐making about procedure selection, novel bariatric procedures, enhanced recovery after bariatric surgery protocols, and logistical concerns (including cost factors) in the current health care arena. There are 85 numbered recommendations that have updated supporting evidence, of which 61 are revised and 12 are new. Noting that there can be multiple recommendation statements within a single numbered recommendation, there are 31 (13%) Grade A, 42 (17%) Grade B, 72 (29%) Grade C, and 101 (41%) Grade D recommendations. There are 858 citations, of which 81 (9.4%) are evidence level (EL) 1 (highest), 562 (65.5%) are EL 2, 72 (8.4%) are EL 3, and 143 (16.7%) are EL 4 (lowest). Conclusions Bariatric procedures remain a safe and effective intervention for higher‐risk patients with obesity. Clinical decision‐making should be evidence based within the context of a chronic disease. A team approach to perioperative care is mandatory, with special attention to nutritional and metabolic issues.
Multidisciplinary patient-centered management of brain metastases and future directions
Palmer, Joshua D. , Gondi, Vinai , Rusthoven, Chad G. , Mishra, Mark V. , Bovi, Joseph , Williams, Nicole , Lustberg, Maryam B. , Brown, Paul D. , Rao, Ganesh , Schild, Steven E. , Palmer, Joshua D , Mishra, Mark V , Lustberg, Maryam , Trifiletti, Daniel M. , Chan, Michael David , Minniti, Giuseppe , Roberge, David

Mayo Clinic

Neuro-Oncology Advances | March 16, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaa034 | PMID 32793882 Get It

Abstract The incidence of brain metastasis is increasing as improvements in systemic therapy lead to increased survival. This provides new and challenging clinical decisions for patients who are trying to balance the risk of recurrence or progression with treatment-related side effects, and it requires appropriate management strategies from multidisciplinary teams. Improvements in prognostic assessment and systemic therapy with increasing activity in the brain allow for individualized care to better guide the use of local therapies and/or systemic therapy. Here, we review the current landscape of brain-directed therapy for the treatment of brain metastasis in the context of recent improved systemic treatment options. We also discuss emerging treatment strategies including targeted therapies for patients with actionable mutations, immunotherapy, modern whole-brain radiation therapy, radiosurgery, surgery, and clinical trials.
Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review
Suarez‐Kelly, Lorena P. , Kimbrough, Charles W. , Abbott, Daniel E. , Pokrzywa, Courtney , Raoof, Mustafa , Lee, Byrne , Grotz, Travis E. , Leiting, Jennifer L. , Dineen, Seán , Powers, Benjamin D. , Veerapong, Jula , Baumgartner, Joel , Russell, Marti C., Zaidi, M., Dhar, Vikrom K. , Lambert, Laura , Hendrix, Ryan J. , Abdel‐Misih, Sherif , Cloyd, Jordan M. , Suarez-Kelly, Lorena P , Pokrzywa, Courtney , Grotz, Travis E , Dineen, Sean P , Hendrix, Ryan J , Abdel-Misih, Sherif , Powers, Benjamin , Dhar, Vikrom , Beal, Eliza Wright , Johnston, Fabian M , Greer, Jonathan B. , Fournier, Keith F. , Lee, Andrew , Clarke, Callisia N. , Mogal, Harveshp , Zaidi, Mohammed Y., Patel, Sameer H , Hays, John L.

Mayo Clinic

Journal of Clinical Medicine | March 12, 2020 | Volume: 9 | Issue: 3 | Pages: 748

10.3390/jcm9030748 | PMID 32164300 Get It

Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal cancer index score (12.1 + 7.9 vs. 14.3 + 8.5, p = 0.034). There was no significant difference in grade III/IV complications (22.4% vs. 16.7%, p = 0.650), readmission (32.3% vs. 23.5%, p = 0.114), or 30-day mortality (1.5% vs. 2.9%, p = 0.411) between groups. NAC patients experienced longer overall survival (OS) (median 32.7 vs. 22.0 months, p = 0.044) but similar recurrence-free survival (RFS) (median 13.8 vs. 13.0 months, p = 0.456). After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80) or RFS (OR 1.04). Among patients who underwent CRS+/-HIPEC for CR-PM, the use of NAC was associated with improved OS that did not persist on multivariable analysis. However, NAC prior to CRS+/-HIPEC was a safe and feasible strategy for CR-PM, which may aid in the appropriate selection of patients for aggressive cytoreductive surgery.
Whole genome sequencing to characterize luminal-type breast cancer.
Ding, Li , Shen, Dong , Wallis, John W., Goldstein, Theodore C. , Allred, D. Craig, Leitch, A. Marilyn , Ota, David M., Bose, Ron , Wilson, Richard K. , Ellis, Matthew J. , Luo, Jingqin , Suman, Vera J. , Goiffon, Reece , Chen, Ken , Olson, John A. , Watson, Mark A , Piwnica‐Worms, David , Stuart, Joshua M. , Hunt, Kelly K. , Mardis, Elaine R.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: 503-503

10.1200/jco.2012.30.15_suppl.503 Get It

503 Background: To correlate clinical features of estrogen receptor positive breast cancer with somatic mutations, massively parallel sequencing (MPS) was applied to tumor and normal DNAs accrued from patients treated with neoadjuvant aromatase inhibitors (AI). Methods: MPS was applied to 77 baseline tumor biopsy samples from the preoperative letrozole trial (JACS 2009: 208, 906) and the Z1031 trial (JCO 2011: 29, 2342) followed by targeted sequencing in another 240 trial samples. Standard statistical approaches were used to compare mutation status and clinical parameters and pathway-based correlation was used to assess interactions between signaling perturbations induced by gene mutations and response to neoadjuvant AI. Results: Eighteen genes were significantly mutated above background. Aside from PIK3CA mutations, the list is dominated by loss-of-function mutations in tumor suppressor genes. Five (RUNX1, CBFP, MYH9, MLL3 and SF3B1) have been previously linked to benign and malignant hematopoietic disorders. Clinical correlation revealed that TP53 mutation was associated with PAM50 LumB status, high-grade histology and high proliferation rates whereas loss-of-function mutations in MAP3K1 associate with PAM50 lumA status, low proliferation rates, and low grade histology. Mutations in GATA3 were associated with greater suppression of proliferation upon AI treatment suggesting mutGATA3 may predict endocrine response. Notably, mutations in MAP3K1 were more common in PIK3CA mutant cases, suggesting cooperation. Pathway analysis demonstrated that rare MAP2K4 mutations produce similar pathway perturbations as MAP3K1 mutation, a logical finding since MAP2K4 is a substrate for MAP3K1. Signaling network patterns driven by lncRNA MALAT1 mutations were associated with multiple poor clinical outcome features. Rare mutations in druggable kinases included two in the kinase domain of HER2. Conclusions: Tumor heterogeneity in luminal-type breast cancer is driven by specific patterns of somatic mutations, however most druggable or potentially prognostic mutations are infrequent. Prospective clinical trials based on these findings will require comprehensive genome sequencing approaches and large scale investigations.
Association of Neighborhood Measures of Social Determinants of Health With Breast, Cervical, and Colorectal Cancer Screening Rates in the US Midwest
Kurani, Shaheen , Inselman, Jonathan , Giblon, Rachel , Bunkers, Kari S., Stroebel, Robert J. , Rushlow, David , Shah, Nilay D. , Kurani, Shaheen S, Lampman, Michelle A. , Doubeni, Chyke A. , Inselman, Jonathan W, Giblon, Rachel E., McCoy, Rozalina G. , Rutten, Lila J. Finney , Chawla, Sagar

Mayo Clinic

JAMA Network Open | March 9, 2020 | Volume: 3 | Issue: 3 | Pages: e200618

10.1001/jamanetworkopen.2020.0618 | PMID 32150271 Get It